CN118416069A - 用卡博特韦和利匹韦林治疗hiv的方法 - Google Patents
用卡博特韦和利匹韦林治疗hiv的方法 Download PDFInfo
- Publication number
- CN118416069A CN118416069A CN202410349180.8A CN202410349180A CN118416069A CN 118416069 A CN118416069 A CN 118416069A CN 202410349180 A CN202410349180 A CN 202410349180A CN 118416069 A CN118416069 A CN 118416069A
- Authority
- CN
- China
- Prior art keywords
- salt
- rilpivirine
- cabotegravir
- once
- days
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Virology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Dermatology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Organic Chemistry (AREA)
- AIDS & HIV (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Inorganic Chemistry (AREA)
- Biochemistry (AREA)
- Engineering & Computer Science (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (10)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962908882P | 2019-10-01 | 2019-10-01 | |
| US201962908995P | 2019-10-01 | 2019-10-01 | |
| US62/908,995 | 2019-10-01 | ||
| US62/908,882 | 2019-10-01 | ||
| US202063037782P | 2020-06-11 | 2020-06-11 | |
| US63/037,782 | 2020-06-11 | ||
| US202063052214P | 2020-07-15 | 2020-07-15 | |
| US63/052,214 | 2020-07-15 | ||
| CN202080069721.1A CN114502166A (zh) | 2019-10-01 | 2020-10-01 | 用卡博特韦和利匹韦林治疗hiv的方法 |
| PCT/IB2020/059185 WO2021064618A1 (en) | 2019-10-01 | 2020-10-01 | Method for treating hiv with cabotegravir and rilpivirine |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202080069721.1A Division CN114502166A (zh) | 2019-10-01 | 2020-10-01 | 用卡博特韦和利匹韦林治疗hiv的方法 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN118416069A true CN118416069A (zh) | 2024-08-02 |
Family
ID=72826936
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202410349180.8A Pending CN118416069A (zh) | 2019-10-01 | 2020-10-01 | 用卡博特韦和利匹韦林治疗hiv的方法 |
| CN202080069721.1A Pending CN114502166A (zh) | 2019-10-01 | 2020-10-01 | 用卡博特韦和利匹韦林治疗hiv的方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202080069721.1A Pending CN114502166A (zh) | 2019-10-01 | 2020-10-01 | 用卡博特韦和利匹韦林治疗hiv的方法 |
Country Status (11)
| Country | Link |
|---|---|
| US (3) | US20220347174A1 (https=) |
| EP (1) | EP4037661A1 (https=) |
| JP (1) | JP7791083B2 (https=) |
| KR (1) | KR20220074880A (https=) |
| CN (2) | CN118416069A (https=) |
| AU (1) | AU2020358156B2 (https=) |
| CA (1) | CA3155587A1 (https=) |
| CL (1) | CL2022000790A1 (https=) |
| IL (1) | IL290716A (https=) |
| MX (1) | MX2022003945A (https=) |
| WO (1) | WO2021064618A1 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN120053445A (zh) | 2018-07-16 | 2025-05-30 | 吉利德科学公司 | 用于治疗hiv的衣壳抑制剂 |
| WO2023222754A1 (en) * | 2022-05-17 | 2023-11-23 | Janssen Sciences Ireland Unlimited Company | Rilpivirine for use in the treatment or prevention of hiv infection |
| WO2023222755A1 (en) * | 2022-05-17 | 2023-11-23 | Janssen Sciences Ireland Unlimited Company | Treatment or prevention of hiv infection |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL2480220T3 (pl) * | 2009-09-22 | 2015-10-30 | Janssen Sciences Ireland Uc | Leczenie i zapobieganie zakażeniu HIV |
| KR20200031658A (ko) * | 2017-07-21 | 2020-03-24 | 비이브 헬쓰케어 컴퍼니 | Hib 감염 및 aids를 치료하기 위한 요법 |
| CN109568328A (zh) * | 2017-09-29 | 2019-04-05 | 重庆药友制药有限责任公司 | 一种用于预防和治疗hiv感染的药物组合物 |
| LT3986561T (lt) * | 2019-06-19 | 2024-04-25 | VIIV Healthcare UK (No.5) Limited | Pirido[2,3-d]pirimidino dariniai kaip žmogaus imunodeficito viruso replikacijos inhibitoriai |
-
2020
- 2020-10-01 US US17/763,076 patent/US20220347174A1/en not_active Abandoned
- 2020-10-01 CA CA3155587A patent/CA3155587A1/en active Pending
- 2020-10-01 JP JP2022520291A patent/JP7791083B2/ja active Active
- 2020-10-01 MX MX2022003945A patent/MX2022003945A/es unknown
- 2020-10-01 WO PCT/IB2020/059185 patent/WO2021064618A1/en not_active Ceased
- 2020-10-01 CN CN202410349180.8A patent/CN118416069A/zh active Pending
- 2020-10-01 KR KR1020227010390A patent/KR20220074880A/ko active Pending
- 2020-10-01 EP EP20789687.9A patent/EP4037661A1/en active Pending
- 2020-10-01 CN CN202080069721.1A patent/CN114502166A/zh active Pending
- 2020-10-01 AU AU2020358156A patent/AU2020358156B2/en active Active
-
2022
- 2022-02-17 IL IL290716A patent/IL290716A/en unknown
- 2022-03-30 CL CL2022000790A patent/CL2022000790A1/es unknown
-
2025
- 2025-06-04 US US19/227,593 patent/US20250302829A1/en active Pending
- 2025-06-04 US US19/227,609 patent/US20250302830A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US20250302830A1 (en) | 2025-10-02 |
| AU2020358156B2 (en) | 2024-06-06 |
| IL290716A (en) | 2022-04-01 |
| CA3155587A1 (en) | 2021-04-08 |
| WO2021064618A1 (en) | 2021-04-08 |
| EP4037661A1 (en) | 2022-08-10 |
| KR20220074880A (ko) | 2022-06-03 |
| US20250302829A1 (en) | 2025-10-02 |
| CN114502166A (zh) | 2022-05-13 |
| JP2022550828A (ja) | 2022-12-05 |
| JP7791083B2 (ja) | 2025-12-23 |
| CL2022000790A1 (es) | 2022-11-25 |
| AU2020358156A1 (en) | 2022-04-21 |
| US20220347174A1 (en) | 2022-11-03 |
| MX2022003945A (es) | 2022-04-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Deeks | Bictegravir/Emtricitabine/Tenofovir Alafenamide: A Review in HIV-1 Infection: ED Deeks | |
| US20250302829A1 (en) | Method for treating hiv with cabotegravir and rilpivirine | |
| US20200113917A1 (en) | 19-nor c3,3-disubstituted c21-n-pyrazolyl steroid and methods of use thereof | |
| JP2025111701A (ja) | 大うつ病性障害および産後うつ病の処置における使用のための１９－ノルｃ３，３－二置換ｃ２１－ｎ－ピラゾリルステロイド | |
| KR20240148425A (ko) | Cns-관련 장애의 치료를 위한 신경활성 스테로이드 | |
| CN111032158A (zh) | 用于治疗抑郁的nk-1拮抗剂组合物和方法 | |
| Rivera et al. | HIV pre-exposure prophylaxis: new and upcoming drugs to address the HIV epidemic | |
| Yu et al. | Pharmacokinetic drug-drug interactions involving antiretroviral agents: an update | |
| JP7287906B2 (ja) | 組み合わせ並びにその使用及びそれによる治療 | |
| Dirajlal-Fargo et al. | Pediatric antiretroviral therapy | |
| RU2840867C1 (ru) | Способ лечения вич каботегравиром и рилпивирином | |
| Koren et al. | Scientific basis of antiretroviral therapy | |
| US20240091159A1 (en) | Combination and Uses and Treatments Thereof | |
| US20220096487A1 (en) | Methods for treating hiv with dolutegravir and lamivudine | |
| Spagnuolo et al. | Lenacapavir for the Treatment of Heavily Treatment-experienced People with Multi-class Resistant HIV. | |
| Pandit et al. | PRINCIPLES AND SCIENTIFIC BASIS OF HIV THERAPY | |
| Ballon | New drugs | |
| WO2014193589A1 (en) | Cancer treatment method | |
| Flamm | Highlights in the Treatment of Hepatitis C Virus From the 2016 AASLD Liver Meeting | |
| Tablets | FULL PRESCRIBING INFORMATION 1 INDICATIONS AND USAGE | |
| ULC et al. | Pr Mylan-Efavirenz | |
| Blonk et al. | and David M. Burger | |
| Francisco | Data Released from Startmrk Study of Isentress Versus Efavirenz |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |